It was disclosed in a ‘late-breaking’ presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Madrid, Spain.
"Our strategy to tackle difficult to treat bacterial infections, such as gonorrhoea, is clear: to develop new mechanism antibiotics that are genuinely innovative treatment options with the potential to replace existing standards of care," said Dr David Roblin, Summit president of research and development.
He added: "We are encouraged by the profile of the series of gonorrhoea antibiotic candidates developed using our proprietary genetics-based discovery platform, and we look forward to selecting a preclinical candidate in the second half of this year."
Summit noted that gonorrhoea is an area of high unmet medical need with only one treatment option recommended by the US Centres for Disease Control, and, additionally, it is identified as a priority pathogen by the World Health Organisation.
The company highlighted that data presented at ECCMID showed a high potency against a range of gonorrhoea strains, including ones that were multi-drug resistant, high selectivity for gonorrhoea which minimises collateral damage to the microbiome.
Additionally, there was low potential for resistance development, and suitability for oral administration, it added.
Summit said it intends to select a candidate to enter studies in the second half of this year.